References
- Greaves MW. Chronic urticaria. N Engl J Med. 1995; 332 1767–72
- Kaplan AP. Clinical practice. Chronic urticaria and angioedema. N Engl J Med. 2002; 346: 175–9
- Greaves M. Chronic urticaria. J Allergy Clin Immunol. 2000; 105: 664–72
- Hellgren L. The prevalence of urticaria in the total population. Acta Allergol. 1972; 27: 236–40
- Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol. 2007; 99 190–3
- Ortonne JP. Chronic idiopathic urticaria for the generalist. Eur J Intern Med. 2003; 14: 148–57
- Kozel MM, Sabroe RA. Chronic urticaria: Aetiology, management and current and future treatment options. Drugs. 2004; 64: 2515–36
- Vonakis BM, Vasagar K, Gibbons SP, Jr, Gober L, Sterba PM, Chang H, et al. Basophil FcεRI histamine release parallels expression of Src-homology 2-containing inositol phosphates in chronic idiopathic urticaria. J Allergy Clin Immunol. 2007; 119: 441–8
- Sabroe RA, Greaves MW. The pathogenesis of chronic idiopathic urticaria. Arch Dermatol. 1997; 133: 1003–8
- Bae JS, Kim SH, Ye YM, Yoon HJ, Suh CH, Nahm DH, et al. Significant association of FcεRIε promoter polymorphisms with aspirin-intolerant chronic urticaria. J Allergy Clin Immunol. 2007; 119: 449–56
- Negro-Alvarez JM, Miralles-Lopez JC. Chronic idiopathic urticaria treatment. Allergol Immunopathol (Madr). 2001; 29: 129–32
- Mateus C. Treatment of chronic idiopathic urticaria unresponsive to type 1 antihistamines in monotherapy. Ann Dermatol Venereol. 2003; 130((Spec No 1))1S129–44
- Lippert U, Artuc M, Grützkau A, Babina M, Guhl S, Haase I, et al. Human skin mast cells express H2 and H4, but not H3 receptors. J Invest Dermatol. 2004; 123: 116–23
- Bagenstose SE, Levin L, Bernstein JA. The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results. J Allergy Clin Immunol. 2004; 113: 134–40
- Mc Bayne TO, Siddall OM. Montelukast treatment of urticaria. Ann Pharmacother. 2006; 40: 939–42
- Tharp MD. Chronic urticaria: Pathophysiology and treatment approaches. J Allergy Clin Immunol. 1996; 98((suppl))325–30
- Guerrero Nurrer GB. Urticaria. Rev Alerg Mex. 1997; 44: 17–22
- Kaplain AP. Chronic urticaria: Pathogenesis and treatment. J Allergy Clin Immunol. 2004; 114: 465–74, quiz 475
- Baker R, Vasagar K, Ohameje N, Gober L, Chen SC, Sterba PM, et al. Basophil histamine release activity and disease severity in chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2008; 100: 244–9
- Leonardi S, Marchese G, Marseglia GL, La Rosa M. Montelukast in allergic diseases beyond asthma. Allergy Asthma Proc. 2007; 28: 287–91
- Sabroe RA, Seed PT, Francis DM, Barr RM, Black AK, Greaves MW. Chronic idiopathic urticaria: Comparison of the clinical features of patients with and without anti-FcεRI or anti-IgE autoantibodies. J Am Acad Dermatol. 1999; 40: 443–50
- Schad CA, Skoner DP. Antihistamines in the pediatric population: Achieving optimal outcomes when treating seasonal allergy rhinitis and chronic urticaria. Allergy Asthma Proc. 2008; 29: 7–13
- Dubuske LM. Levocetirizine: The latest treatment option for allergic rhinitis and chronic idiopathic urticaria. Allergy Asthma Proc. 2007; 28: 724–34
- Meltzer EO, Gillman SA. Efficacy of fexofenadine versus desloratadine in suppressing histamine-induced wheal and fare. Allergy Asthma Proc. 2007; 28: 67–73
- Brodell LA, Beck LA. Differential diagnosis of chronic urticaria. Ann Allergy Asthma Immunol. 2008; 100: 188–90